Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07455084 · ClinicalTrials.gov registry record · Phase 1
A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults
A Phase 1 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Not yet
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT07455084 is a Phase 1 study that has not yet begun recruiting, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 8 participants.
The verdict
NCT07455084, a Phase 1 study, has not yet begun recruiting, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of the present trial is to obtain information on the absorption, distribution, metabolism, excretion and pharmacokinetics (PK) of 14C-SEP-380135 and its metabolites following a single oral dose.
Interventions
- DRUG 14C-SEP-380135
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-03-20 |
| Est. Completion | 2026-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07455084
The ClinicalTrials.gov registry entry for NCT07455084 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 14C-SEP-380135 is the first listed.
NCT07455084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07455084 about?
NCT07455084 is a clinical study titled "A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults". The purpose of the present trial is to obtain information on the absorption, distribution, metabolism, excretion and pharmacokinetics (PK) of 14C-SEP-380135 and its metabolites following a single oral dose.
What is the current status of trial NCT07455084?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2026-03-20. Estimated completion is 2026-05-03.
What interventions are being tested in trial NCT07455084?
The interventions under investigation include: 14C-SEP-380135 (DRUG).
Who is sponsoring clinical trial NCT07455084?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.